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Received August 19, 2014; accepted May 14, 2015AbstractBackground: The newly developed magnetic-resonance-imaging (MRI) hepatocyte-specific contrast agent, gadoli-
niumeethoxybenzylediethylenetriamine pentaacetic acid (GdeEOBeDTPA), has different excretion pathways from the conventional MRI
contrast agent, gadoliniumediethylenetriamine pentaacetic acid (GdeDTPA). In this study, we compare the enhancement effect of the liver and
renal parenchyma between these two contrast agents for patients with liver cirrhosis.
Methods: We retrospectively included 49 consecutive patients with liver cirrhosis who underwent GdeDTPA- and GdeEOBeDTPA-enhanced
MRIs within 3 months. We measured the signal intensity of the liver and kidney, and calculated the enhancement ratio (ER) in the arterial phase,
portal venous phase, and venous phase (VP). We also calculated a delayed phase (DP) when GdeDTPAwas used, and a hepatocyte phase (HP)
when GdeEOBeDTPA was used. The ERs were compared between the two contrast agents. The effect of liver function on the ERs was also
evaluated.
Results: The ER of the liver with GdeEOBeDTPA was significantly higher than with GdeDTPA in the VP ( p ¼ 0.01) and in the HP/DP
( p ¼ 0.01). The ER of the kidney in the DP with GdeDTPA was significantly higher than in the HP with GdeEOBeDTPA ( p < 0.001). The
ERs of the liver using GdeEOBeDTPA for patients with normal serum bilirubin were significantly higher than those with abnormal levels
( p ¼ 0.047), but there was no significant difference using GdeDTPA.
Conclusion: The enhancement effect of the liver parenchyma using both MRI contrast agents was not affected by the degree of liver cirrhosis or
abnormal liver function. However, it was affected by the serum-bilirubin levels in the GdeEOBeDTPA-enhanced MRIs. Furthermore,
enhancement of the liver was higher when using GdeEOBeDTPA in the VP, DP, and HP. This knowledge is helpful when performing dynamic
MRIs to diagnose focal hepatic lesions in the heterogeneous liver parenchyma.
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Magnetic resonance imaging (MRI) has become an
important diagnostic modality for hepatic tumors. With ad-
vances in hardware and three-dimensional reconstruction
techniques, MRIs can shorten the acquisition time and provide
better imaging quality.1e3 Contrast-enhanced images are
important for diagnosing hypervascular tumors, such as he-
patocellular carcinomas (HCCs).4e6 The paramagnetic object,
gadolinium (Gd), combined with the chelating agent, dieth-
ylenetriamine pentaacetic acid (DTPA), has been used as an
MRI contrast agent for a long time. When injected intrave-
nously, it distributes throughout the extracellular fluid, pro-
ducing contrast enhancement in the T1-weighted image, and
provides dynamic-enhanced information. GdeDTPA is then
completely excreted by the urinary system.
There are several hepatocyte-specific contrast agents, such as
superparamagnetic iron oxide nanoparticles, gadobenate dime-
glumine, and gadoliniumeethoxybenzylediethylenetriamine
pentaacetic acid (GdeEOBeDTPA).7e9 GdeEOBeDTPA is a
newly developed hepatocyte-specific contrast agent with com-
bined perfusion and hepatocyte-selective properties. With the
lipophilic ethobenzyl group, it can enter hepatocytes via an
organic anion-transport system, and is excreted into the biliary
system (43.1e53.2%) and urinary system (41.6e51.2%)
separately.8e11
The information obtained from contrast-enhanced MRIs
provides different enhancement features for hepatic tumors
and helps in the differential diagnosis. However, contrast up-
take of the background liver parenchyma affects the appear-
ance of hepatic tumors. The hepatic and renal functions may
lead to different contrast uptakes of the liver parenchyma,
especially for hepatocyte-specific contrast agents.12e14 Most
patients undergo GdeEOBeDTPA-enhanced MRIs for the
diagnosis of hepatic tumors, especially HCCs. Most of the
HCCs develop in abnormal livers, such as those with diffuse
liver disease or liver cirrhosis. The underlying liver disease,
liver function, and renal function may play important roles in
the diagnostic ability of contrast-enhanced MRIs. The
different excretion pathways between GdeEOBeDTPA and
GdeDTPA may also affect the enhancing pattern. The purpose
of this study was to compare the differences in the enhance-
ment of the liver and kidney between GdeDTPA and
GdeEOBeDTPA for patients with liver cirrhosis.
2. Methods2.1. SubjectsThis study was approved by the Institutional Review Board
of our hospital. We retrospectively included consecutive pa-
tients with hepatic tumors and liver cirrhosis. The inclusion
criteria for patients were (1) having liver cirrhosis and the
presence of hepatic tumors; (2) having no previously existing
malignancy or treatment history; and (3) having undergone
both GdeDTPA- and GdeEOBeDTPA-enhanced MRIs
within the past 3 months. A total of 49 patients (32 men and 17women; mean age: 59 years old, range: 28e80 years old)
enrolled in this study from December 2009 to March 2012.
Among them, all patients had liver cirrhosis (39 hepatitis B
virus-related cirrhosis, 5 hepatitis C virus-related cirrhosis, 3
alcoholic cirrhosis, 1 both hepatitis B þ C virus related, and 1
hepatitis B virus-related and alcoholic cirrhosis; 38 Child-
ePugh class A disease, 9 ChildePugh class B disease, and 2
ChildePugh class C disease). Furthermore, we divided the
patients into two groups (normal/abnormal) according to their
serum-bilirubin levels and aspartate aminotransferase/alanine
transaminase (AST/ALT), respectively, to assess the different
enhancement effects in the serum bilirubin, AST/ALT, and
ChildePugh classifications.2.2. Imaging methodsThe MRIs were performed with a Achieva 1.5 T MRI
scanner (Philips Healthcare, Eindhoven, The Netherlands) and
a phased-array body coil. Prior to contrast-agent administra-
tion, turbo spin echo T2WI [repetition time/echo time (TR/
TE): 1000e1800/110 milliseconds; slice thickness: 8 mm;
gap: 0.8 mm; matrix: 192  256; turbo-spin-echo factor: 24;
number of average (NEX): 2; flip angle: 90; field of view
(FOV): 38e40 cm] with and without fat saturation, and cor-
onal T2WI were obtained under a respiratory trigger. Dual
T1WI (TR/TE: 180/2.3/4.6; slice thickness: 8 mm; matrix:
192  256; NEX: 1; flip angle: 10; FOV: 38e40 cm) and fat
sat T1WI were performed during one breath hold. Automatic
shimming was used for fat-suppression imaging to maximize
the magnetic-field homogeneity. Flow compensation was also
used.
All patients received 0.1 mmol/kg GdeDTPA (Magnevist;
Bayer Schering Pharma AG, Berlin, Germany) for the
GdeDTPA-enhanced MRI examination. All of them received
0.025 mmol/kg GdeEOBeDTPA (Primovist; Bayer Schering
Pharma AG) for the GdeEOBeDTPA-enhanced MRI. The
contrast agent was injected as a bolus at a speed of nearly
2 mL/second through peripheral veins. Dynamic three-
dimensional T1-weighted fast-field-echo sequence (TR/TE:
5e10/3.3 milliseconds; slice thickness: 5 mm; matrix:
192  256; NEX: 1; flip angle: 10; FOV: 38e40 cm) was
carried out before, in 8e20 seconds [arterial phase (AP)],
50e55 seconds [portal venous phase (PP)], and 85e90 sec-
onds [venous phase (VP)] following the contrast-agent injec-
tion. In addition, delayed-phase (DP) images (180 seconds
after the injection of the contrast agent) were acquired when
GdeDTPA was used, and hepatocyte-phase (HP) images (20
minutes after the injection of the contrast agent) were acquired
when the GdeEOBeDTPA was used.2.3. Imaging analysisTwo experienced radiologists with more than 15 years'
experience in abdominal MRI reviewed all the GdeDTPA- and
GdeEOBeDTPA-enhanced MRI images. Any difference of
opinion between the two radiologists was resolved by a third
radiologist who was also blinded to the clinical information.
Table 1
Enhancement ratios in the liver and kidney in the dynamic study, delayed, and
hepatocyte phases obtained with gadoliniumediethylenetriamine pentaacetic
acid and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid.
Organ Phase Contrast p
GdeDTPA GdeEOBeDTPA
Liver AP 0.14 ± 0.20 0.18 ± 0.22 0.52
PP 0.44 ± 0.24 0.51 ± 0.19 0.25
VP 0.32 ± 0.44 0.47 ± 0.46 0.01*
DP/HP 0.33 ± 0.45 0.49 ± 0.53 0.01*
Kidney
(cortex þ medulla)
AP 1.89 ± 0.93 1.95 ± 0.69 0.76
PP 2.35 ± 0.98 2.48 ± 0.77 0.53
VP 2.47 ± 1.75 2.34 ± 1.30 0.54
DP/HP 2.89 ± 2.43 1.32 ± 1.18 <0.001*
Cortex AP 1.12 ± 0.53 0.99 ± 0.35 0.19
PP 1.07 ± 0.50 1.28 ± 0.43 0.03*
VP 0.94 ± 0.75 1.20 ± 0.69 0.01*
DP/HP 1.09 ± 1.01 0.62 ± 0.58 <0.001*
Medulla AP 0.77 ± 0.51 0.96 ± 0.39 0.12
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nostic workstation (GE Healthcare, Milwaukee, WI, USA).
The signal intensities (SIs) of the liver and kidney were
measured by the radiologists using regions of interest (ROI).
Each ROI was a circle or oval. For measurements of the liver
parenchyma, the ROI with an area of at least 200 mm2 was
placed at a location in the right posterior segment and devoid of
large vessels. For SI measurements of the kidney, the image
was magnified up to two times because of the organ's small
size. The ROI with an area of at least 10 mm2 was located in
the bilateral renal cortex and medulla. The SIs were measured
twice and the measurements averaged. The enhancement ratio
(ER) of the liver and kidney at all phases was calculated from
the SI measurements before (SI pre) and after (SI post)
administration of GdeDTPA or GdeEOBeDTPA. The ratio is
(SI post e SI pre)/SI pre. The differences in the ERs between
the two contrast agents were evaluated.PP 1.28 ± 0.53 1.20 ± 0.37 0.53
VP 1.54 ± 1.03 1.14 ± 0.62 0.001*
DP/HP 1.80 ± 1.43 0.70 ± 0.65 <0.001*2.4. Statistical analysis*Statistically significant ( p < 0.05).
AP ¼ arterial phase; DP ¼ delayed phase; GdeDTPA ¼ gadoliniume
diethylenetriamine pentaacetic acid; GdeEOBeDTPA ¼ gadoliniume
ethoxybenzylediethylenetriamine pentaacetic acid; HP ¼ hepatocyte phase;
PP¼ portal venous phase; VP¼ venous phase.
Fig. 1. Time-enhanced curve of enhancement ratios of the liver and kidney ob-
tained with gadoliniumediethylenetriamine pentaacetic acid and gadoli-
niumeethoxybenzylediethylenetriamine pentaacetic acid. AP ¼ arterial phase;
DP ¼ delayed phase; ER ¼ enhancement ratio; GdeDTPA ¼ gadoliniume
diethylenetriamine pentaacetic acid; GdeEOBeDTPA ¼ gadoliniume
ethoxybenzylediethylenetriamine pentaacetic acid; HP ¼ hepatocyte phase;
PP¼ portal venous phase; VP ¼ venous phase.The data were presented as mean ± standard deviation. The
different ERs from the GdeDTPA and GdeEOBeDTPA for
the liver, renal cortex, and renal medulla at all phases were
compared by linear mixed models. The linear mixed model
was also used to analyze the differences in the ERs for the
GdeDTPA and GdeEOBeDTPA in the different serum bili-
rubin, AST/ALT, and ChildePugh classifications. Interob-
server differences between the two observers were evaluated
with the kappa test and interpreted as moderate for 0.4 <
k  0.60, good for 0.6 < k  0.80, and excellent for k > 0.80.
Statistical analyses were performed using SAS (version 9.2;
SAS Inc., Cary, NC, USA). A p value of <0.05 was considered
statistically significant.
3. Results
The interobserver agreement by the kappa analysis showed
excellent agreement (k ¼ 0.91). The ER results of the liver and
kidney at dynamic study, DP, and HP obtained with
GdeDTPA and GdeEOBeDTPA are summarized in Table 1.
Comparing the enhancement effect of the liver between the
GdeDTPA and GdeEOBeDTPA, the ER of the liver in VP
with GdeEOBeDTPA (0.47 ± 0.46) was significantly higher
than with GdeDTPA (0.32 ± 0.44) ( p ¼ 0.01). The ER in HP
with GdeEOBeDTPA (0.49 ± 0.53) was significantly higher
than in DP with GdeDTPA (0.33 ± 0.45) ( p ¼ 0.01) (Figs. 1
and 2). Over all the phases, the average ER of the liver with
GdeEOBeDTPA (0.40 ± 0.42) was significantly higher than
with GdeDTPA (0.28 ± 0.35) ( p ¼ 0.004).
The ERs of the renal cortex in PP and VP with
GdeEOBeDTPA were significantly higher than with
GdeDTPA ( p ¼ 0.03; p ¼ 0.01). The ER of the renal medulla
in VP with GdeDTPA (1.54 ± 1.03) was significantly higher
than with GdeEOBeDTPA (1.14 ± 0.62) ( p ¼ 0.001).
However, the average ER of the whole kidney (the average ER
of the renal cortex and medulla) in DP with GdeDTPA was
significantly higher than in HP with GdeEOBeDTPA( p < 0.0001) (Figs. 1 and 3). Over all the phases, the ER of
the whole kidney with GdeDTPA (1.16 ± 0.86) was signifi-
cantly higher than with GdeEOBeDTPA (0.99 ± 0.67)
( p ¼ 0.01).
The differences between the ERs of the liver and kidney in
the dynamic phases and HP obtained from GdeDTPA and
GdeEOBeDTPA for different serum bilirubin, AST/ALT, and
ChildePugh classifications are summarized in Tables 2 and 3.
In the GdeDTPA-enhanced MRI, the ERs of the liver and
kidney showed no significant difference between the patients
with normal and abnormal liver functions (such as serum
bilirubin, AST, and ALT). There were also no significant
differences between the patients using the ChildePugh clas-
sification. However, the ERs of the liver in the HP using
Fig. 2. A 42-year-old man. (A) Precontrast image, (B) arterial phase, (C) portal venous phase (PP), (D) venous phase, and (E) delayed phase of the liver with a
gadoliniumediethylenetriamine pentaacetic acid (GdeDTPA)-enhanced magnetic resonance imaging, and (F) precontrast image, (G) arterial phase, (H) PP, (I)
venous phase, and (J) hepatocyte phase of a gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid (GdeEOBeDTPA)-enhanced magnetic resonance
imaging. The enhancement ratios (ERs) of the liver with GdeDTPA reached peak enhancement in PP, and then decreased. However, the ERs of the liver with
GdeEOBeDTPA maintained enhancement. The ERs of the liver in hepatocyte phase with GdeEOBeDTPAwere significantly higher than in delayed phase with
GdeDTPA.
Fig. 3. A 42-year-old man. (A) Precontrast image, (B) arterial phase, (C) portal venous phase (PP), (D) venous phase, and (E) delayed phase (DP) of the kidney
with a gadoliniumediethylenetriamine pentaacetic acid (GdeDTPA)-enhanced magnetic resonance imaging, and (F) precontrast image, (G) arterial phase, (H) PP,
(I) venous phase, and (J) hepatocyte phase of a gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid (GdeEOBeDTPA)-enhanced magnetic resonance
imaging. The enhancement ratios (ERs) of the kidney with GdeDTPA maintained enhancement and reached peak enhancement in DP. However, the ERs of the
kidney with GdeEOBeDTPA reached peak enhancement in PP, and then decreased. The ERs of the kidney in DP with GdeDTPAwere significantly higher than in
hepatocyte phase with GdeEOBeDTPA.
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were significantly higher than for patients with abnormal
serum bilirubin ( p ¼ 0.047). In the different AST/ALT and
ChildePugh classifications, the ERs of the liver and kidney
using GdeEOBeDTPA showed no significant differences.
4. Discussion
In contrast-enhanced imaging studies, the enhancement of
the liver parenchyma influences the detection of hepatic le-
sions. To diagnose nodular lesions in patients with liver
cirrhosis is difficult in daily practice due to the heterogeneous
enhancement of the background liver. GdeEOBeDTPA is a
hepatocyte-specific MRI contrast agent, and is excreted
through both the biliary and urinary systems. It is different
from the traditional extracellular MRI contrast agent,
GdeDTPA, which is excreted exclusively through the urinary
system. Many studies have discussed the enhancement pat-
terns of different lesions with GdeEOBeDTPA,7,15 but fewhave discussed the enhancement of the liver and kidney pa-
renchyma.16 In the present study, we compared the enhance-
ment effect of the liver and renal parenchyma between these
two contrast agents for patients with liver cirrhosis. Our results
showed that the ER of the liver with GdeEOBeDTPA was
significantly higher than with GdeDTPA in the VP ( p ¼ 0.01)
and in the HP/DP ( p ¼ 0.01). The ER of the kidney in the DP
with GdeDTPA was significantly higher than in the HP with
GdeEOBeDTPA ( p < 0.001). The different enhancement
may be due to their different excretion pathways.10
Tamada et al17 compared the AP, VP, and DP (about 180
seconds after the injection of the contrast agent) between these
two contrast agents. Their results showed that the enhance-
ments of the liver parenchyma and whole kidney in the AP
with GdeEOBeDTPAwere lower than those with GdeDTPA.
Conversely, the enhancement of the liver parenchyma during
the DP with GdeEOBeDTPA was higher.17 Our results were
similar in the PP and VP, but there was no significant differ-
ence in the AP. According to the American Association for the
Table 2
Enhancement ratios in the liver and kidney in the dynamic study, delayed, and
hepatocyte phases obtained with gadoliniumediethylenetriamine pentaacetic
acid and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid ac-
cording to ChildePugh classification.
Contrast Organ Phase ChildePugh classification
A (n ¼ 38) B (n ¼ 9) C (n ¼ 2)
GdeDTPA Liver AP 0.11 ± 0.18 0.21 ± 0.19 0.47 ± 0.37
PP 0.42 ± 0.24 0.53 ± 0.25 0.45 ± 0.16
VP 0.26 ± 0.44 0.50 ± 0.42 0.68 ± 0.32
DP 0.23 ± 0.39 0.68 ± 0.51 0.63 ± 0.32
Kidney AP 1.81 ± 0.89 2.13 ± 1.09 2.37 ± 1.45
PP 2.31 ± 0.98 2.42 ± 1.09 2.68 ± 0.72
VP 2.37 ± 1.83 2.85 ± 1.64 2.61 ± 0.42
DP 2.61 ± 2.27 4.23 ± 2.98 2.32 ± 0.53
GdeEOBeDTPA Liver AP 0.17 ± 0.62 0.14 ± 0.33 0.58 ± 0.21
PP 0.52 ± 0.14 0.44 ± 0.27 0.79 ± 0.32
VP 0.44 ± 0.50 0.56 ± 0.29 0.77 ± 0.24
HP 0.46 ± 0.58 0.54 ± 0.33 0.69 ± 0.07
Kidney AP 2.00 ± 0.1 1.85 ± 1.02 1.45 ± 0.20
PP 2.56 ± 0.73 2.28 ± 0.96 1.93 ± 0.32
VP 2.28 ± 1.36 2.77 ± 1.03 1.48 ± 0.92
HP 1.25 ± 1.31 1.63 ± 0.59 1.35 ± 0.47
All the data were not statistically significant ( p > 0.05).
AP ¼ arterial phase; DP ¼ delayed phase; GdeDTPA ¼ gadoliniume
diethylenetriamine pentaacetic acid; GdeEOBeDTPA ¼ gadoliniume
ethoxybenzylediethylenetriamine pentaacetic acid; HP ¼ hepatocyte phase;
PP ¼ portal venous phase; VP¼ venous phase.
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is hypervascular in the AP and washout in the late phase or
DP.18 Lesion detection is influenced by contrast enhancement
of the lesions themselves and the background tissue. Ac-
cording to our results, there may be no difference in the
detection of arterial hypervascularity in the liver using both
contrast agents. However, the higher enhancement of the liverTable 3
Enhancement ratios in the liver and kidney in the dynamic study, delayed, and hep
and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid according to t
Contrast Organ Phase Total bilirubina
Abnormal (n ¼ 32) Normal (n
GdeDTPA Liver AP 0.19 ± 0.19 0.11 ± 0.2
PP 0.52 ± 0.20 0.40 ± 0.2
VP 0.44 ± 0.48 0.26 ± 0.4
DP 0.45 ± 0.51 0.26 ± 0.4
Kidney AP 1.97 ± 0.94 1.84 ± 0.9
PP 2.60 ± 1.09 2.23 ± 0.9
VP 2.80 ± 1.84 2.29 ± 1.7
DP 3.45 ± 2.70 2.60 ± 2.2
Gd-EOB-DTPA Liver AP 0.16 ± 0.29 0.19 ± 0.1
PP 0.47 ± 0.25 0.54 ± 0.1
VP 0.42 ± 0.36 0.50 ± 0.5
HP 0.34 ± 0.45 0.56 ± 0.5
Kidney AP 1.82 ± 0.77 2.02 ± 0.6
PP 2.34 ± 0.89 2.56 ± 0.7
VP 2.34 ± 1.20 2.34 ± 1.3
HP 1.35 ± 1.28 1.31 ± 1.1
*Statistically significant ( p < 0.05).
ALT ¼ alanine transaminase; AP ¼ arterial phase; AST ¼ aminotransferase; DP ¼
GdeEOBeDTPA ¼ gadoliniumeethoxybenzylediethylenetriamine pentaacetic ac
a Serum-bilirubin level <1.2 mg/dL was defined as normal, and 1.2 mg/dL wa
b AST/ALT level <42 U/L was defined as normal, and 42 U/L was defined asparenchyma in the late phase and DP in the GdeEOBeDTPA-
enhanced MRI may increase the liver-to-lesion contrast and
help in detecting the washout phenomenon of HCC. In the HP
of the GdeEOBeDTPA-enhanced MRI, our results were
similar to those of previous studies. The uptake of the liver
parenchyma in the HP increased the liver-to-lesion contrast
and increased the detection of liver lesions.16,19e22 We suggest
that GdeEOBeDTPA could provide better diagnostic infor-
mation than GdeDTPA in the VP, DP, and HP. Some studies
have indicated that insufficient liver enhancement is related to
the patient's liver dysfunction.23,24
Some studies have also evaluated the impact of liver-
function factors for liver parenchymal enhancement with
GdeEOBeDTPA with different conclusions.12,13,25,26 In this
study, we assessed the ERs in the liver in the dynamic study,
DP, and HP obtained from GdeDTPA and GdeEOBeDTPA
based on the serum-bilirubin level, AST/ALT, and Child-
ePugh classifications. There was no difference between the
normal and abnormal AST/ALT. However, a higher ER was
found in patients with normal serum-bilirubin level signifi-
cantly. GdeEOBeDTPA is a hepatocyte-specific MRI
contrast agent approximately 50% of which is excreted
through the biliary system.10 Previous literature had reported
that serum-bilirubin levels are related to the function of
excretion; they may affect the liver enhancement in
GdeEOBeDTPA-enhanced MRIs.25,26 Our study used a
serum-bilirubin level of 1.2 mg/dL to divide the patients into
normal and abnormal groups, while Tajima et al13 used
1.3 mg/dL. The liver enhancements were lower in patients
with abnormal bilirubin levels than in those with normal
bilirubin levels in both our study and in previous ones; the
abnormal serum-bilirubin levels may affect the lesion-
detection ability of GdeEOBeDTPA-enhanced MRIs.atocyte phases obtained with gadoliniumediethylenetriamine pentaacetic acid
he total bilirubin and aspartate aminotransferase/alanine transaminase.
p AST/ALTb p
¼ 17) Abnormal (n ¼ 20) Normal (n ¼ 29)
1 0.45 0.13 ± 0.21 0.15 ± 0.19 0.45
5 0.26 0.45 ± 0.25 0.43 ± 0.21 0.26
2 0.09 0.29 ± 0.43 0.37 ± 0.47 0.09
0 0.07 0.29 ± 0.43 0.39 ± 0.48 0.07
5 0.79 1.94 ± 0.94 1.80 ± 0.95 0.79
2 0.51 2.30 ± 1.09 2.42 ± 0.79 0.51
0 0.31 2.44 ± 1.79 2.52 ± 1.72 0.31
6 0.08 2.79 ± 2.40 3.08 ± 2.52 0.08
7 0.80 0.17 ± 0.23 0.19 ± 0.20 0.84
4 0.53 0.53 ± 0.19 0.49 ± 0.18 0.75
1 0.43 0.44 ± 0.44 0.53 ± 0.50 0.46
6 0.047* 0.40 ± 0.51 0.56 ± 0.57 0.27
4 0.51 1.95 ± 0.69 1.96 ± 0.70 0.96
0 0.48 2.43 ± 0.81 2.57 ± 0.72 0.63
6 0.98 2.31 ± 1.22 2.40 ± 1.46 0.78
5 0.90 1.27 ± 1.14 1.41 ± 1.28 0.68
delayed phase; GdeDTPA ¼ gadoliniumediethylenetriamine pentaacetic acid;
id; HP ¼ hepatocyte phase; PP ¼ portal venous phase; VP ¼ venous phase.
s defined as abnormal.
abnormal.
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tion, which combines five factors (serum albumin, bilirubin
levels, prothrombin activity, ascites levels, and the presence or
absence of hepatic encephalopathy), was able to indicate liver
function more accurately and significantly correlated with
liver enhancement. Kim et al26 indicated that the liver paren-
chymal enhancement of GdeEOBeDTPAwas affected by the
ChildePugh classification. Chou et al19 showed that the
enhancement of the liver for patients with ChildePugh class C
was lower than for those of class A and class B, but no sig-
nificant difference was found. In our study, there were no
significant differences between the ChildePugh classes, but
the number of patients with ChildePugh classes B and C was
relatively small as compared to class A. Therefore, we suggest
that future studies should include more patients with classes B
and C for further evaluation.
The ER data of renal cortex and medulla were different in
every phase for both contrast agents. However, the significant
differences were noted mainly in VP and DP/HP. Overall, the
ERs of the kidney with GdeDTPA were significantly higher
than with GdeEOBeDTPA at DP/HP, which may be due to
the excretion of GdeDTPA exclusively into the urinary sys-
tem. The serum bilirubin, AST/ALT, and ChildePugh classi-
fications did not affect the enhancement of the kidney with
either GdeDTPA or GdeEOBeDTPA.
This study had several limitations. First, the number of
ChildePugh class B and class C patients was relatively small
in the present study; however, the proportions of patients based
on the ChildePugh score represent a similar distribution for
the general population. Other studies showed a similar distri-
bution.12,19,26 Future studies with a large-enough number of
patients to cover all the ChildePugh classifications could
define a clearer relationship between the liver enhancement
and the ChildePugh classification. Second, the delay time of
the two contrast agents was different. The delay time for
GdeDTPA is 180 seconds, and the delay time for
GdeEOBeDTPA is 20 minutes. This may be due to the
different excretion routes of the two contrast agents. Previous
studies also suggested using the different delay times for daily
practice.9,27 Therefore, using different delay times to compare
the two contrast agents is acceptable.
In conclusion, the enhancement effect of the liver with
GdeEOBeDTPA was higher than with GdeDTPA in the VP
and DP. Conversely, the enhancement effect of the kidney with
GdeDTPA was significantly higher than with
GdeEOBeDTPA in the DP. The enhancement effect of the
liver was not affected by liver cirrhosis or abnormal liver
function. However, the enhancement of the liver in the HP of
GdeEOBeDTPA-enhanced MRI could be affected by the
serum-bilirubin levels. GdeEOBeDTPA is helpful when
performing dynamic MRIs and in the HP for diagnosing focal
hepatic lesions in the heterogeneous liver parenchyma.
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